Fig. 1. Framework of developing a guideline for cervical cancer screening. ① Benefits of pap test screening, ② harms of pap test screening, ③ accuracy.

Slides:

Advertisements

Similar presentations

Progress Against Cervical Cancer. 1980–1989 Progress Against Cervical Cancer 1980– –1984: HPV virus is discovered to cause cervical cancer.

Advertisements

Cervical Screening Guidelines - for now and the future - Meg McLachlin, MD, FRCPC.

ASHLYN SAVAGE, MD, MSCR ASSOCIATE PROFESSOR OBSTETRICS AND GYNECOLOGY MEDICAL UNIVERSITY OF SOUTH CAROLINA Managing Abnormal Pap Smears: Incorporating.

Figure 1.1 The observer in the truck sees the ball move in a vertical path when thrown upward. (b) The Earth observer views the path of the ball as a parabola.

Clinical Uses of HPV DNA Testing

Cervical cancer screening in Estonia: present situation Piret Veerus Department of Epidemiology and Biostatistics National Institute for Health Development.

Cervical cancer prevention update

January is Cervical Health Awareness Month. Mt. Prospect Health Ministry wants you to know that there’s a lot you can do to prevent cervical cancer.

A Cervical Cancer Decision Model to Inform Recommendations About Preventive Services Perspective of the Decision Modeler Shalini Kulasingam, PhD Duke University.

Review of the Guidelines for Cervical Screening in New Zealand Presentation for smear-takers September 2008.

Cervical Cancer in California Janet Bates, MD MPH Research Program Director Research and Surveillance Program California Cancer Registry.

Cervical Cancer Screening Recommendations 2012, FDA Panel 2014.

SoftPAP® A Novel Collection Device for Cervical Cytology.

The Future Control of Cervical Cancer Hazel Lewis Public Health Physician Wellington Cartwright Forum, 7 August 2015.

Hot Topics Clinical Medicine ACHA Annual Meeting Boston, MA May 31, 2013.

The ThinPrep ® PapTest ™ PAUL SULTANA MLS Thursday, 22 October 2015.

Implementing Best Practices in Cervical Cancer Screening

HPV as Primary Screening for Cervical Cancer: Ready for Prime Time? ACOG Annual Clinical Meeting May 4, 2015.

Cervical Cancer Screening Measure Updates (CMS #124)

Screening of genital cancers Evidence Based Presented by Dr\ Heba Nour.

HPV and Pap Guidelines Jennifer Johnson MD. Objectives 1. Define the new PAP guidelines. 2. Identify the historical trends and new evidence resulting.

Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Cervical Cancer Screening With Both Human Papillomavirus.

“Take the Test: Not the Risk” HPV and Cervical Cancer Cervical Cancer is Preventable!

Update on Cervical Cancer Screening Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Health System Ann Arbor, Michigan.

1 Cervical Cancer Screening Updates Dr. GORDON JOHNSON.

THE NEW CERVICAL CANCER SCREENING PROGRAM

Cervical Cancer Screening

Cancer prevention and early detection

Public Health England leads the NHS Screening Programmes

Ontario Colposcopy Clinical Guidance 2016

Cancer prevention and early detection

Performance of mRNA- and DNA-based high-risk human papillomavirus assays in detection of high-grade cervical lesions ELINA VIRTANEN1, ILKKA KALLIALA2,3,

NEW SCREENING PROTOCOL WITH DUAL-STAINED CYTOLOGY TRIAGE

Trreatment of Preinvasive Lesions

Colposcopic Biopsy Results of HPV 16 and 18 patients in Bartın

Cancer Screening Guidelines

Cervical Cancer in California

Can HPV vaccine have other health benefits more than cancer prevention

Viral infections and cancer

HPV VACCINATION ——1st vaccine against cancer

Ontario Colposcopy Clinical Guidance 2016

Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment.

HPV DNA SCREENING, FROM CO-TESTING

Retest in 12mo with HPV testing

Updates on Pap Smear Guidelines 2014

Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study Alejandra Castanon, MD, Rebecca Landy, PhD,

Navigating the Data and Evolving Our Approach

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Economic evaluation of vaccination: capturing the full benefits, with an application to human papillomavirus T. Bärnighausen, D.E. Bloom, E.T. Cafiero,

Clinical significance of signal pattern of high-risk human papillomavirus using a novel fluorescence in situ hybridization assay in cervical cytology

The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional.

The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional.

Concordant testing results between various human papillomavirus assays in primary cervical cancer screening: systematic review L. de Thurah, J. Bonde,

Public Health England leads the NHS Screening Programmes

Volume 136, Issue 2, Pages (February 2015)

Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

BIOE 301 Lecture Sixteen.

Figure 1: Guidelines for primary cytology# screening in South Africa

The experience of Cervical Cancer

Task Force on Cervical Cancer Screening in Estonia

Primary HPV test screening

Cervical excisional treatment of young women: A population-based study

Volume 153, Issue 1, Pages (April 2019)

Oncogenic Human Papillomavirus: Application of CRISPR/Cas9 Therapeutic Strategies for Cervical Cancer Cell Physiol Biochem 2017;44:2455– DOI: /

Fig. 3. The examinations consumed by the three cervical screening strategies to detect CIN2+/CIN3+. (A) The cases of CIN2+ detected by three current cervical.

Fig. 2. Three cervical screening strategies to detect CIN2+/CIN3+

Fig. 1. Flowchart of inclusion and exclusion criteria of the study population.ASC-US, atypical squamous cells of undetermined significance; CIN, cervical.

American Society of Cytopathology’s CELL Talks

Presentation transcript:

Fig. 1. Framework of developing a guideline for cervical cancer screening. ① Benefits of pap test screening, ② harms of pap test screening, ③ accuracy and harm of liquid based cytology (LBC), ④ benefits of human papillomavirus (HPV) primary test or cotest, ⑤ harms of HPV primary test or cotest, ⑥ target age and interval of cervical cancer screening, and ⑦ specific population group for cervical cancer. Fig. 1. Framework of developing a guideline for cervical cancer screening. ① Benefits of pap test screening, ② harms of pap test screening, ③ accuracy and harm of liquid based cytology (LBC), ④ benefits of human papillomavirus (HPV) primary test or cotest, ⑤ harms of HPV primary test or cotest, ⑥ target age and interval of cervical cancer screening, and . . . J Gynecol Oncol. 2015 Jul;26(3):232-239. http://dx.doi.org/10.3802/jgo.2015.26.3.232